← All Sponsors

SPONSOR

Institute of Hematology & Blood Diseases Hospital, China

Total Trials

33

Recruiting

33

Phases

Phase 2, Phase 4, Phase 1, Phase 2, Phase 1, EARLY_Phase 1

Conditions studied: Primary Immune Thrombocytopenia Relapsed/Refractory Large B-Cell Lymphoma Hemophilia A With Inhibitor Mucormycosis in Hematologic Malignancies Lymphoma, T-Cell NK-LGL Leukemia T-LGL Leukemia Immune Thrombocytopenia Treatment Autoimmune Hemolytic Anemia

NCT06658834 Phase 2

A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

Primary Immune Thrombocytopenia

NCT06489808 Phase 2

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Relapsed/Refractory Large B-Cell Lymphoma

NCT05888870 Phase 4

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Mucormycosis in Hematologic Malignancies

NCT06530550 Phase 2

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-Cell

NCT06776510 Phase 1, Phase 2

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia

NCT06212154 Phase 1

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Autoimmune Hemolytic Anemia

NCT05914662 Phase 2

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

Waldenstrom Macroglobulinemia

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

NCT06611839 Phase 1, Phase 2

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

NCT05709288 Phase 1

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

NCT06880354 Phase 1

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

Thrombotic Microangiopathies

NCT06613880 Phase 2

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

Aplastic Anemia

Cohort of Nursing Homes

NCT07406139 Phase 4

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

Transfusion-dependent Beta-Thalassemia

NCT07304232 Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

Allogeneic Hematopoietic Cell Transplantation (HCT)

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Transplant-Related Disorder

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Philadelphia Chromosome Negative ALL

Gene Therapy for Chinese Hemophilia A

NCT05599256 Phase 2

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Transplant-Related Disorder

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

NCT07010237 Phase 2

Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia

Sever Aplastic Anaemia

NCT07063199 Phase 2

Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

NCT06799611 Phase 2

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)

NCT05913804 Phase 1

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

NCT06783790 Phase 2

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

AML (Acute Myelogenous Leukemia)

NCT04600960 Phase 2

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia

Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients

Thrombocytopenia

NCT07212335 EARLY_Phase 1

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

Immune Effector Cell Associated Hematotoxicity

NCT06387121 Phase 2

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06244368 Phase 2

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Peripheral T Cell Lymphoma